NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BLRX

Bioline Rx Ltd ADR

Apr 28 • 04:00PM ET

3.18

Dollar change -0.04
Percentage change -1.09	%

Healthcare • Biotechnology • Israel • NASD

Peers: BPMC ARGX MGNX ONCY AFMD ADAP IMMP KPTI CTMX FATE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.55	Insider Own	0.56%	Shs Outstand	3.72M	Perf Week	9.83%
Market Cap	11.85M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.00%	Shs Float	3.70M	Perf Month	-0.16%
Income	-9.22M	PEG	-	EPS next Q	-0.95	Inst Own	1.33%	Short Float	5.87%	Perf Quarter	-24.17%
Sales	28.94M	P/S	0.41	EPS this Y	62.78%	Inst Trans	67.12%	Short Ratio	3.22	Perf Half Y	-81.21%
Book/sh	6.04	P/B	0.53	EPS next Y	87.24%	ROA	-17.93%	Short Interest	0.22M	Perf Year	-87.01%
Cash/sh	5.26	P/C	0.61	EPS next 5Y	68.36%	ROE	-69.11%	52W Range	2.30 - 35.60	Perf YTD	-62.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.38%	ROI	-39.24%	52W High	-91.05%	Beta	1.15
Dividend TTM	-	Quick Ratio	1.56	Sales past 5Y	100.58%	Gross Margin	65.33%	52W Low	38.47%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	1.76	EPS Y/Y TTM	88.01%	Oper. Margin	-67.03%	RSI (14)	55.66	Volatility	6.10% 8.33%
Employees	28	Debt/Eq	1.12	Sales Y/Y TTM	502.92%	Profit Margin	-31.86%	Recom	2.00	Target Price	33.00
Option/Short	Yes / Yes	LT Debt/Eq	0.75	EPS Q/Q	80.44%	Payout	-	Rel Volume	0.17	Prev Close	3.22
Sales Surprise	52.18%	EPS Surprise	-57.31%	Sales Q/Q	144.77%	Earnings	Mar 31 BMO	Avg Volume	67.54K	Price	3.18
SMA20	11.91%	SMA50	0.88%	SMA200	-77.57%	Trades		Volume	11,302	Change	-1.09%

Date	Action	Analyst	Rating Change	Price Target Change
May-18-17	Upgrade	Maxim Group	Hold → Buy	$1 → $3
Feb-13-17	Initiated	Rodman & Renshaw	Buy	$3
Aug-12-16	Downgrade	Maxim Group	Buy → Hold	$4 → $1
Aug-17-15	Reiterated	Maxim Group	Buy	$8 → $4
Jul-27-15	Reiterated	ROTH Capital	Buy	$10.50 → $7
Jun-22-15	Initiated	JMP Securities	Mkt Outperform	$5

Apr-02-25 05:00PM	BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ... (GuruFocus.com) +6.16% -5.16%
Mar-31-25 10:52AM	BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
07:00AM	BioLineRx Reports 2024 Financial Results and Provides Corporate Update (PR Newswire)
Mar-24-25 07:00AM	BioLineRx to Report 2024 Annual Results on March 31, 2025 (PR Newswire)
Jan-21-25 07:00AM	BioLineRx Issues Letter to Shareholders (PR Newswire)
07:00AM	Loading…
Jan-17-25 07:00AM	BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares (PR Newswire) -16.74%
Jan-06-25 08:57AM	BioLineRx Announces $10 Million Registered Direct Offering (PR Newswire) -40.87%
Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-26-24 10:00AM	BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts (GuruFocus.com)
Nov-25-24 07:00AM	BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value (PR Newswire)
Nov-22-24 06:35AM	BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell (TipRanks) -13.97%
Nov-21-24 06:30AM	BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. (PR Newswire) -40.71%
Nov-20-24 07:19AM	BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 (PR Newswire)
Nov-05-24 09:00AM	BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 (PR Newswire)
Oct-16-24 07:00AM	BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide (PR Newswire) +7.40%
01:01PM	Loading…
Sep-17-24 01:01PM	BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection (PR Newswire)
Aug-15-24 07:00AM	BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire) -12.48%
Aug-08-24 07:00AM	BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 (PR Newswire) +6.36%
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
May-30-24 07:00AM	BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) (PR Newswire) +18.81%
May-29-24 08:03AM	BioLineRx Ltd. (NASDAQ:BLRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-28-24 11:53AM	BLRX Stock Earnings: BioLine Rx Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
May-24-24 07:00AM	BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (PR Newswire) +13.24%
May-22-24 07:00AM	BioLineRx to Report First Quarter 2024 Results on May 28, 2024 (PR Newswire)
May-17-24 05:00PM	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
May-06-24 07:00AM	BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 (PR Newswire) +5.63%
Apr-17-24 07:00AM	BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting (PR Newswire)
Apr-10-24 07:00AM	BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement (PR Newswire)
09:00AM	Loading…
Apr-01-24 09:00AM	BioLineRx Announces $6 Million Registered Direct Offering (PR Newswire) -23.20%
Mar-27-24 12:23PM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.77%
Mar-26-24 07:00AM	BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire) -20.77%
Mar-20-24 07:00AM	BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 (PR Newswire)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-04-24 07:00AM	BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production (PR Newswire)
Feb-28-24 07:00AM	BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire) +7.32%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-16-24 07:00AM	BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® (PR Newswire) +13.12%
Dec-21-23 07:00AM	BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire) +5.06%
Nov-21-23 03:45PM	BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Nov-20-23 07:00AM	BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-13-23 07:00AM	BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 (PR Newswire)
Nov-02-23 03:12PM	3 Tech Stocks That Wall Street Loves More Than Nvidia (InvestorPlace)
Oct-31-23 09:00AM	BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures (PR Newswire) +12.78%
Oct-30-23 11:38AM	3 Top Penny Stocks to Make You a Millionaire in 5 Years (InvestorPlace)
Oct-12-23 07:00AM	BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment (PR Newswire)
Sep-28-23 07:00AM	BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) (PR Newswire)
Sep-19-23 07:00AM	BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer (PR Newswire) +11.44%
Sep-14-23 05:36AM	BLRX: Go! (Zacks) +6.02%
Sep-11-23 07:00AM	BioLineRx Announces FDA Approval of APHEXDA (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma (PR Newswire)
Sep-05-23 06:04AM	BLRX: On Your Marks, Get Set (Zacks) +21.29%
Aug-31-23 08:18AM	BioLineRx Ltd. (NASDAQ:BLRX) Q2 2023 Earnings Call Transcript (Insider Monkey) +25.90%
Aug-30-23 07:00AM	BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Aug-22-23 07:00AM	BioLineRx to Report Second Quarter 2023 Results on August 30, 2023 (PR Newswire)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-18-23 03:22PM	3 Smart Penny Stocks with Huge Potential (InvestorPlace)
Jul-17-23 07:00AM	BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide (PR Newswire)
Jun-29-23 02:00PM	The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023 (InvestorPlace)
Jun-07-23 05:25AM	BLRX: First Quarter Results (Zacks Small Cap Research)
May-24-23 07:00AM	BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
May-17-23 07:00AM	BioLineRx to Report First Quarter 2023 Results on May 24, 2023 (PR Newswire) +11.11%
May-04-23 01:56PM	7 High-Potential Penny Stocks in the Biotech Sector (InvestorPlace)
Apr-25-23 07:00AM	BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Apr-17-23 11:00AM	BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma (PR Newswire)
Apr-04-23 08:21PM	The 3 Best Biotech Stocks Under $1 to Buy for April (InvestorPlace)
Mar-24-23 07:15AM	BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 11:42AM	BLRX: Confidence in a Strong Launch (Zacks Small Cap Research)
Mar-22-23 07:00AM	BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Mar-15-23 07:00AM	BioLineRx to Report 2022 Annual Financial Results on March 22, 2023 (PR Newswire)
Mar-06-23 07:00AM	BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease (PR Newswire)
Jan-04-23 07:00AM	BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer (PR Newswire) +6.72%
Dec-20-22 12:36PM	BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate (Benzinga)
07:00AM	BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors (PR Newswire)
Dec-05-22 04:00AM	BLRX: Self-Commercialization in the US (Zacks Small Cap Research)
Nov-28-22 04:30PM	BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event (PR Newswire)
Nov-15-22 07:00AM	BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates (PR Newswire)
Nov-10-22 04:30PM	BioLineRx to Report Third Quarter 2022 Results on November 15, 2022 (PR Newswire) -24.00% +6.67%
07:00AM	BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization (PR Newswire)
Nov-04-22 04:30PM	BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire)
Nov-03-22 09:11AM	BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Nov-02-22 09:21AM	BLRX: Cast Off the Bowlines: Aphexda Commercialization (Zacks Small Cap Research)
Sep-27-22 07:00AM	BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization (PR Newswire)
Sep-19-22 08:00AM	BioLineRx Announces $15 Million Registered Direct Offering (PR Newswire) -33.77%
Sep-15-22 12:38PM	BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer (Benzinga)
07:00AM	BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital (PR Newswire)
Sep-12-22 07:00AM	BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization (PR Newswire) -9.89%
Aug-18-22 07:47AM	BLRX: September NDA (Zacks Small Cap Research)
Aug-16-22 07:00AM	BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -6.28%
Aug-11-22 07:00AM	BioLineRx to Report Second Quarter 2022 Results on August 16, 2022 (PR Newswire)
Jun-29-22 08:00AM	BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures (PR Newswire) -5.38%
Jun-28-22 07:00AM	BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC) (PR Newswire)
Jun-16-22 07:00AM	BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer (PR Newswire)
May-12-22 10:16AM	BLRX: First Quarter 2022 Operational and Financial Results (Zacks Small Cap Research)
May-11-22 07:00AM	BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) -12.40%
May-05-22 07:00AM	BioLineRx to Report First Quarter 2022 Results on May 11, 2022 (PR Newswire)
Mar-17-22 08:55AM	BLRX: 2021 Results (Zacks Small Cap Research)
Mar-16-22 07:00AM	BioLineRx Reports Year-End 2021 Financial Results and Provides Corporate Update (PR Newswire)
Mar-10-22 07:00AM	BioLineRx to Report 2021 Annual Results on March 16, 2022 (PR Newswire)
Mar-03-22 07:00AM	BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization (PR Newswire)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLRX

Bioline Rx Ltd ADR

Upgrade your FINVIZ experience